Human papillomavirus-related squamous cell carcinoma

Researchers are testing a vaccine called BNT113 in people whose cancers are driven by HPV16, a common virus linked to head and neck, cervical, and anogenital tumors. The trial enrolls two groups: one with head and neck cancer that has been treated and shows no signs of disease, a…

This study tested whether an education program helps low-income, uninsured adults aged 18-45 accept and complete a free HPV vaccine series. The goal is to prevent HPV-related cancers. About 100 participants took part, and researchers tracked how many started and finished the vacc…

This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system's attack on tumors. The trial includes 39…

This study looks at whether giving less radiation after surgery for HPV-positive throat cancer can still prevent the cancer from coming back while causing fewer long-term side effects. About 83 adults with HPV-positive oropharyngeal cancer will receive either a standard or reduce…

This trial tests a personalized approach to radiation therapy for people with HPV-related oropharynx cancer. Doctors use PET-CT scans taken before and during treatment to see how well the tumor is responding. If the response is good, the radiation dose is reduced, which may lesse…

This study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…

This phase 2 trial tested a new approach for people with intermediate-risk HPV-related head and neck cancer. Participants received an HPV-16 vaccine (ISA101b) plus the immunotherapy drug pembrolizumab alongside standard chemoradiation. The goal was to see if this combination coul…

This study tested whether giving less intense treatment after surgery for HPV-related throat cancer can reduce side effects like weight loss and the need for a feeding tube. 63 patients had surgery and then received either lower-dose radiation or no radiation, depending on their …

This study tested a new experimental treatment called HPVST cells in 32 people with HPV-related cancers that had returned or not responded to standard care. The cells are grown from the patient's own blood and trained to attack HPV-infected cancer cells. The goal was to find a sa…

This trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…

This early-phase study tested a new drug called CUE-101, alone or with pembrolizumab, in 80 adults with HPV16-positive head and neck cancer that had spread or returned. The main goals were to check safety and find the right dose. Researchers also looked at whether the drug helped…

This early-stage trial tested a new type of cell therapy for people with HPV-positive head & neck or cervical cancer. The treatment uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some patients also received cells that produce an a…

This early-phase study tested a shorter, more intense radiation schedule (completed in 3 weeks instead of the usual 6) combined with chemotherapy for people with HPV-related throat cancer. The goal was to find the safest dose that still controls the cancer. Only 24 patients took …

This completed phase I/II trial tested two experimental vaccines, HB-201 and HB-202, in 198 people with HPV 16+ cancers. The goal was to find a safe dose and see if the vaccines could shrink tumors. Participants received the vaccines alone or with standard treatments like pembrol…

This early-phase trial tested a new drug called TGN-S11, alone and combined with the immunotherapy Keytruda, in 28 patients with advanced HPV-related cancers that had come back or spread. The main goal was to find a safe dose and see how the body handles the drug. Results will he…

This study tested a new mouthwash-based DNA test to see if it can find HPV in saliva, which might help detect HPV-related throat cancer early. Researchers compared results from 360 people — some with throat cancer and some without. The goal was to see how accurate the test is at …

This study tested a new blood test (liquid biopsy) to see if it could find any cancer left behind after surgery in 103 people with HPV-related head and neck cancer. The goal was to catch remaining disease early, which could help doctors decide if more treatment is needed. The tes…

This study looked at 460 people with HIV to see what types of cancer they have and why some choose to join cancer clinical trials. Researchers tracked cancers like Kaposi sarcoma, lymphoma, and HPV-related tumors. They also used surveys to learn how HIV and cancer treatments affe…

This study tested whether a mathematical model could help doctors choose the best radiation schedule for people with HPV-positive throat cancer. The goal was to see if personalized dosing could shrink tumors faster than standard treatment. Fifty-five adults took part, and researc…

This completed study looked at how well the HPV vaccine protects against HPV infections over time in over 3,000 Rwandan women aged 18-28, some living with HIV and some without. Researchers collected blood, oral, and other samples to measure vaccine effectiveness and long-term ant…

This study looked at 49 people with sinonasal cancer to see if high-risk HPV, tobacco, alcohol, or drug use play a role. Researchers tested tumor samples for HPV and compared risk factors by gender and race. The goal is to better understand what causes these rare cancers.

This study looked at 662 patients with HPV-positive throat cancer that had spread or come back. Researchers wanted to see how patients were treated with pembrolizumab (Keytruda) or nivolumab (Opdivo), with or without chemotherapy, in real-world settings. The goal was to gather in…